knowledge -WSS

knowledge

author：fashion 2025-09-03 03:31:57 - browse：289

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Long Covid needs a new name — and a new frame

hotspot

WSS

FTC loses bid to block Novant's North Carolina hospital merger

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Food makers tried to stack nutrition panel with preferred experts

For pregnant people, addiction treatment shouldn't mean a call to child protective services

BD to buy Edwards patient monitoring unit for $4.2 billion

Diverse clinical trials: Why aren’t we there yet?

explore

knowledge

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Generate Biomedicines machine learning biotech raises $273M

In age of alternative facts, a scholarly course on calling out crap

Congress needs to close a vaccine

Psychedelics group wrestles with new pharma identity

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Supreme Court strikes down use of affirmative action

BD to buy Edwards patient monitoring unit for $4.2 billion

Alkermes shareholders re

ASCO Daily Recap: CAR

explore

ASCO Daily Recap: CAR

Congress needs to close a vaccine

Sutter Health’s antitrust win overturned by appeals court

Stopping antidepressants leads to symptoms for 1 in 6 patients

CMS got Medicare Advantage quality rating wrong, judge rules

Elevance PBM president out as customers face prescription chaos

focus

hotspot

knowledge

explore